These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial. Smyth A; Tan KH; Hyman-Taylor P; Mulheran M; Lewis S; Stableforth D; Prof Knox A; Lancet; 2005 Feb 12-18; 365(9459):573-8. PubMed ID: 15708100 [TBL] [Abstract][Full Text] [Related]
4. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children. Rappaz I; Decosterd LA; Bille J; Pilet M; Bélaz N; Roulet M Eur J Pediatr; 2000 Dec; 159(12):919-25. PubMed ID: 11131352 [TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Blumer JL; Saiman L; Konstan MW; Melnick D Chest; 2005 Oct; 128(4):2336-46. PubMed ID: 16236892 [TBL] [Abstract][Full Text] [Related]
6. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics. Vinks AA; Brimicombe RW; Heijerman HG; Bakker W J Antimicrob Chemother; 1997 Jul; 40(1):125-33. PubMed ID: 9249216 [TBL] [Abstract][Full Text] [Related]
7. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis. Vic P; Ategbo S; Turck D; Husson MO; Launay V; Loeuille GA; Sardet A; Deschildre A; Druon D; Arrouet-Lagande C Arch Dis Child; 1998 Jun; 78(6):536-9. PubMed ID: 9713009 [TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model. Cappelletty DM; Kang SL; Palmer SM; Rybak MJ Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921 [TBL] [Abstract][Full Text] [Related]
9. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Benko AS; Cappelletty DM; Kruse JA; Rybak MJ Antimicrob Agents Chemother; 1996 Mar; 40(3):691-5. PubMed ID: 8851594 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. Latzin P; Fehling M; Bauernfeind A; Reinhardt D; Kappler M; Griese M J Cyst Fibros; 2008 Mar; 7(2):142-6. PubMed ID: 17766190 [TBL] [Abstract][Full Text] [Related]
11. Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial. Hewer SCL; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Williamson PR; Lancet Respir Med; 2020 Oct; 8(10):975-986. PubMed ID: 33007285 [TBL] [Abstract][Full Text] [Related]
12. Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis. Prescott WA; Gentile AE; Nagel JL; Pettit RS P T; 2011 Nov; 36(11):723-63. PubMed ID: 22346306 [TBL] [Abstract][Full Text] [Related]
14. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Smith AL; Fiel SB; Mayer-Hamblett N; Ramsey B; Burns JL Chest; 2003 May; 123(5):1495-502. PubMed ID: 12740266 [TBL] [Abstract][Full Text] [Related]
15. Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients. Byl B; Baran D; Jacobs F; Herschuelz A; Thys JP J Antimicrob Chemother; 2001 Aug; 48(2):325-7. PubMed ID: 11481316 [No Abstract] [Full Text] [Related]
16. A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis. Bosso JA; Bonapace CR; Flume PA; White RL Pharmacotherapy; 1999 May; 19(5):620-6. PubMed ID: 10331825 [TBL] [Abstract][Full Text] [Related]